For US Healthcare Professionals Important Safety Information | Full Prescribing Information | Medication Guide | For US Patients | Start Form

Comparable overall rates of TEAEs and SAEs vs Aubagio® (teriflunomide)1

Overall, the proportion of patients experiencing at least 1 treatment-emergent adverse event (TEAE) or serious adverse event (SAE) was similar across treatment groups.1

Adverse reactions (ARs) reported in at least 5% of patients taking PONVORY® and at a higher rate than in patients taking Aubagio®2

Comparable rates of adverse reactions between PONVORY® 20 mg versus Teriflunomide 14 mg

  • The most common ARs (incidence ≥10%) in patients taking PONVORY® were upper respiratory tract infection (37%), hepatic transaminase elevation (23%), and hypertension (10%)2
  • ARs reported in at least 2% to <5% of patients taking PONVORY® and at a higher rate than in patients taking Aubagio® included cough, pain in extremity, somnolence, pyrexia, increase in C-reactive protein, hypercholesterolemia, and vertigo2
  • 82% of patients taking PONVORY® completed 2 years of study treatment, compared with 82.2% of patients taking Aubagio®2

*Includes the following terms: nasopharyngitis, upper respiratory tract infection, pharyngitis, respiratory tract infection, bronchitis, respiratory tract infection viral, viral upper respiratory tract infection, tracheitis, and laryngitis.2

†Includes the following terms: alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, and transaminases increased.2

‡Includes the following terms: hypertension, hypertensive crisis, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased.2

Comparable overall rates of TEAEs and SAEs vs Aubagio®1

Comparable overall rates of TEAEs and SAEs between PONVORY® versus Teriflunomide

Most frequent TEAEs (≥10%) in either group1

Chart comparing safety set between PONVORY® 20 mg versus Teriflunomide 14 mg

Increased ALT and nasopharyngitis were reported more frequently in patients taking PONVORY® than in patients taking Aubagio®.1

Headache and alopecia were more frequently reported in patients taking Aubagio®.1

Upper respiratory tract infection was reported by a similar percentage of PONVORY® and Aubagio® patients.1

Summary of liver test abnormalities1,2

  • The majority (89%) of patients with alanine aminotransferase (ALT) increases ≥3x the upper limit of normal (ULN) continued treatment with PONVORY® with values returning to <3x the ULN within approximately 2 to 4 weeks2
  • All ALT level increases of ≥3 the ULN resolved despite continued treatment with PONVORY® (n = 86) or after treatment discontinuation (n = 11).1
  • ALT increased ≥3x the ULN in 17.3% of patients taking PONVORY® compared with 8.3% of patients taking Aubagio®2
  • ALT increased ≥5x ULN in 4.6% of patients taking PONVORY® compared with 2.5% of patients taking Aubagio®2
  • ALT increased ≥8x ULN in 0.7% of patients taking PONVORY® compared with 2.1% of patients taking Aubagio®1
  • Patients who develop symptoms suggestive of hepatic dysfunction§ should have hepatic enzymes checked. PONVORY® should be discontinued if significant liver injury is confirmed2
Chart of liver test abnormalities between PONVORY® 20 mg versus Teriflunomide 14 mg

ALT = alanine aminotransferase; AST = aspartate aminotransferase; TBIL = total bilirubin; ULN = upper limit of normal.
Central laboratory reference ranges: ALT ULN: 44 U/L (male) and 33 U/L (female); AST ULN: 39 U/L (male) and 34 U/L (female).3

§Such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, or jaundice, and/or dark urine during treatment.2

Patient with preexisting ALT elevation >5x ULN and resolved after discontinuation.3

Effects on heart rate and rhythm on Day 13#

Overview of treatment-emergent heart rate and rhythm (including hypotension) adverse events of special interest (AESI), safety set3

Chart of treatment-emergent heart rate and rhythm safety set between PONVORY® 20 mg versus Teriflunomide 14 mg

First dose monitoring is recommended for select patients2

Because initiation of PONVORY® treatment results in a decrease in heart rate (HR), first dose, 4-hour monitoring is recommended for patients with2:

  • Sinus bradycardia (HR <55 beats per minute [bpm])
  • First- or second-degree atrioventricular (AV) block (Mobitz type I)
  • History of myocardial infarction or heart failure occurring more than 6 months prior to treatment initiation and in stable condition

First dose monitoring should be completed in a setting where resources to appropriately manage symptomatic bradycardia are available.

In all patients, a dose titration is required for initiation of treatment with PONVORY® to help reduce cardiac effects2

In the OPTIMUM study:

  • Bradycardia at treatment initiation and sinus bradycardia on ECG|| occurred in 5.8% of patients taking PONVORY® compared with 1.6% of patients taking Aubagio®2
    • Bradycardia resolved in all patients without intervention and did not require discontinuation of treatment2
  • No second- and third-degree AV blocks were observed. AV conduction delays manifested as first-degree AV block (prolonged PR interval on ECG), which occurred in 3.4% of patients taking PONVORY® and in 1.2% of patients taking Aubagio®2
    • The conduction abnormalities typically were transient, asymptomatic, resolved within 24 hours, resolved without intervention, and did not require discontinuation of treatment with PONVORY®2

AV = atrioventricular; ECG = electrocardiogram.

#These treatment-emergent AESI occurred following the PONVORY® 2 mg dose on Day 1, consistent with titration requirements for PONVORY®.2,3

||Defined as HR <50 bpm.2

50% of patients remained on PONVORY® 20 mg4

In the most recent analysis of an ongoing phase 2, long-term, safety extension study4:

50% of patients remained 
on PONVORY® 20 mg
after 8 years

The median exposure
to PONVORY® 20 mg
was 8 years

  • The data shown represent patients who initiated PONVORY® 20 mg treatment in the core study and continued with 20 mg during TP1 of the extension study4

TP = treatment period.

The study period consisted of a core study lasting 24 weeks and an extension study subdivided into 3 TPs. Additional patients received PONVORY® 10 mg (n = 139) or 40 mg (n = 15) (data not shown). Data were analyzed at the end of TP3 (March 2019). Patients with >8 years of PONVORY® 20 mg treatment exposure: n = 73; total patients receiving PONVORY® 20 mg: N = 145.4

GET INFORMATION about the PONVORY® titration schedule
Start icon
SEE how to start your patients on once-daily PONVORY®
Gear icon
FIND OUT how PONVORY® works

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

PONVORY® is contraindicated in patients who:

  • In the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart failure.
  • Have presence of Mobitz Type II second-degree, third-degree atrioventricular (AV) block, or sick sinus syndrome, or sino-atrial block, unless patient has a functioning pacemaker.

WARNINGS AND PRECAUTIONS

Risk of Infections

PONVORY® causes a dose-dependent reduction in peripheral lymphocyte count to 30-40% of baseline values because of reversible sequestration of lymphocytes in lymphoid tissues. PONVORY® may increase the susceptibility to infections. Life-threatening and rare fatal infections have been reported in association with other sphingosine 1-phosphate (S1P) receptor modulators. Before initiating treatment with PONVORY®, results from a recent complete blood count including lymphocyte count should be reviewed. Monitor for infection during treatment and for 1-2 weeks after discontinuation. Do not start PONVORY® in patients with active infection.

Herpes Viral Infections

Cases of herpes viral infection have been reported in the development program of PONVORY®; herpes simplex encephalitis and varicella zoster meningitis have been reported with other S1P receptor modulators. Patients without a healthcare professional confirmed history of varicella (chickenpox) or without documentation of a full course of vaccination should be tested for antibodies to VZV prior to initiating PONVORY®.

Cryptococcal Infections

Cases of fatal cryptococcal meningitis (CM) and disseminated cryptococcal infections have been reported with other S1P receptor modulators. Physicians should be vigilant for clinical symptoms or signs of CM. Patients with symptoms or signs consistent with a cryptococcal infection should undergo prompt diagnostic evaluation and treatment. PONVORY® treatment should be suspended until a cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.

Progressive Multifocal Leukoencephalopathy (PML)

PML has been reported in patients treated with a S1P receptor modulator and other multiple sclerosis (MS) therapies and has been associated with some risk factors (e.g., immunocompromised patients, polytherapy with immunosuppressants). Longer treatment duration increases the risk of PML in patients treated with S1P receptor modulators with the majority of cases occurring in patients treated for at least 18 months. Physicians should be vigilant for clinical symptoms or magnetic resonance imaging (MRI) findings that may be suggestive of PML. MRI findings may be apparent before clinical signs or symptoms. If PML is suspected, treatment with PONVORY® should be suspended until PML has been excluded.

If PML is confirmed, treatment with PONVORY® should be discontinued.

Immune reconstitution inflammatory syndrome (IRIS) has been reported in patients treated with S1P receptor modulators who developed PML and subsequently discontinued treatment. IRIS presents as a clinical decline in the patient’s condition that may be rapid, can lead to serious neurological complications or death, and is often associated with characteristic changes on MRI. The time to onset of IRIS in patients with PML was generally within a few months after S1P receptor modulator discontinuation. Monitoring for development of IRIS and appropriate treatment of the associated inflammation should be undertaken.

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies

Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be co-administered with caution because of the risk of additive immune system effects.

Vaccinations

Patients without a confirmed history of chickenpox or without documentation of a full course of vaccination against VZV should be tested for antibodies to VZV before initiating PONVORY® treatment. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with PONVORY®, following which initiation of treatment should be postponed for 4 weeks to allow the full effect of vaccination to occur.

No clinical data are available on the efficacy and safety of vaccinations in patients taking PONVORY®. Vaccinations may be less effective if administered during PONVORY® treatment. If live attenuated vaccines are required, administer at least 1 month prior to initiation of PONVORY®. Avoid the use of live attenuated vaccines during and for 1 to 2 weeks after treatment of PONVORY®.

Bradyarrhythmia and Atrioventricular Conduction Delays

Since initiation of PONVORY® treatment results in a transient decrease in heart rate and atrioventricular (AV) conduction delays, an up-titration scheme must be used to reach the maintenance dosage of PONVORY® (20 mg).

Reduction in Heart Rate

Initiation of PONVORY® may result in a transient decrease in heart rate. After the first titration dose of PONVORY®, the decrease in heart rate typically begins within an hour and reaches its nadir within 2-4 hours. The heart rate typically recovers to baseline levels 4-5 hours after administration.

Atrioventricular Conduction Delays

Initiation of PONVORY® treatment has been associated with transient atrioventricular conduction delays that follow a similar temporal pattern as the observed decrease in heart rate during dose titration. If treatment with PONVORY® is considered, advice from a cardiologist should be sought for individuals:

  • With significant QT prolongation (QTc greater than 500 msec).
  • With atrial flutter/fibrillation or arrhythmia treated with Class Ia or Class III anti-arrhythmic drugs.
  • With unstable ischemic heart disease, cardiac decompensated failure occurring more than 6 months prior to treatment initiation, history of cardiac arrest, cerebrovascular disease (TIA, stroke occurring more than 6 months prior to treatment initiation), or uncontrolled hypertension.
  • With a history of Mobitz Type II second degree AV block or higher-grade AV block, sick-sinus syndrome, or sino-atrial heart block.

Obtain an ECG in all patients to determine whether preexisting conduction abnormalities are present. For patients taking other drugs that decrease heart rate, treatment with PONVORY® should generally not be initiated without consultation from a cardiologist because of the potential effect on heart rate. In all patients, a dose titration is recommended for initiation of PONVORY® treatment to help reduce cardiac effects.

Respiratory Effects

Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and reductions in diffusion lung capacity for carbon monoxide (DLCO) were observed in PONVORY®-treated patients mostly occurring in the first month after treatment initiation. Spirometric evaluation of respiratory function should be performed during therapy with PONVORY® if clinically indicated.

Liver Injury

Elevations of transaminases may occur in PONVORY®-treated patients. Obtain transaminase and bilirubin levels, if not recently available (i.e., within last 6 months) before initiation of PONVORY® therapy.

Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, or jaundice and/or dark urine during treatment, should have hepatic enzymes checked. PONVORY® should be discontinued if significant liver injury is confirmed.

No dosage adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). PONVORY® is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh class B and C, respectively).

Increased Blood Pressure

PONVORY®treated patients had an average increase of 2.9 mmHg in systolic blood pressure and 2.8 mmHg in diastolic blood pressure. Blood pressure should be monitored during treatment with PONVORY® and managed appropriately.

Cutaneous Malignancies

The risk of cutaneous malignancies (including basal cell carcinoma (BCC), squamous cell carcinoma, and melanoma) is increased in patients treated with S1P receptor modulators. PONVORY®. may increase the risk of BCC. Skin examinations are recommended prior to or shortly after the start of treatment and periodically thereafter for all patients, particularly those with risk factors for skin cancer. Providers and patients are advised to monitor for suspicious skin lesions. If a suspicious skin lesion is observed, it should be promptly evaluated. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using sunscreen with a high protection factor. Concomitant phototherapy with UV-B radiation or PUVA-photochemotherapy is not recommended in patients taking PONVORY®.

Fetal Risk

Based on animal studies, PONVORY® may cause fetal harm. Because it takes approximately 1 week to eliminate PONVORY® from the body, women of childbearing potential should use effective contraception to avoid pregnancy during and for 1 week after stopping PONVORY® treatment.

Macular Edema

S1P receptor modulators, including PONVORY®, have been associated with an increased risk of macular edema. Conduct an ophthalmic evaluation of the fundus, including the macula, in all patients before starting treatment, periodically while on therapy, and again at any time if a patient reports any change in vision while on PONVORY® therapy. Continuation of therapy in patients with macular edema has not been evaluated. Macular edema over an extended period of time (i.e., 6 months) can lead to permanent visual loss. Consider discontinuing PONVORY if macular edema develops.

Macular Edema in Patients with a History of Uveitis or Diabetes Mellitus

Patients with a history of uveitis and patients with diabetes mellitus are at increased risk of macular edema during therapy with S1P receptor modulators, including PONVORY®. Therefore, these patients should have regular follow-up examinations of the fundus, including the macula, during treatment with PONVORY®.

Posterior Reversible Encephalopathy Syndrome

Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported in patients receiving a sphingosine 1-phosphate (S1P) receptor modulator. Such events have not been reported for PONVORY®-treated patients in the development program. However, should a PONVORY®-treated patient develop any unexpected neurological or psychiatric symptoms/signs (e.g., cognitive deficits, behavioral changes, cortical visual disturbances, or any other neurological cortical symptoms/signs), any symptom/sign suggestive of an increase of intracranial pressure, or accelerated neurological deterioration, the physician should promptly schedule a complete physical and neurological examination and should consider an MRI. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, PONVORY® should be discontinued.

Unintended Additive Immunosuppressive Effects from Prior Treatment with Immunosuppressive or Immune-Modulating Therapies

When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system while at the same time minimizing risk of disease reactivation, when initiating PONVORY®. Initiating treatment with PONVORY® after treatment with alemtuzumab is not recommended.

Severe Increase in Disability After Stopping PONVORY®

Severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of a S1P receptor modulator. The possibility of severe exacerbation of disease should be considered after stopping PONVORY® treatment. Patients should be observed for a severe increase in disability upon PONVORY® discontinuation and appropriate treatment should be instituted, as required.

After stopping PONVORY® in the setting of PML, monitor for development of immune reconstitution inflammatory syndrome (PML-IRIS).

Immune System Effects After Stopping PONVORY®

After stopping PONVORY® therapy, ponesimod remains in the blood for up to 1 week.

Starting other therapies during this interval will result in concomitant exposure to ponesimod. Lymphocyte counts returned to the normal range in 90% of patients within 1 week of stopping therapy, however, residual pharmacodynamics effects, such as lowering effects on peripheral lymphocyte count, may persist for 1 to 2 weeks after the last dose. Use of immunosuppressants within this period may lead to an additive effect on the immune system, and therefore caution should be applied 1 to 2 weeks after the last dose of PONVORY®.

OVERDOSAGE

In patients with overdosage of PONVORY®, especially upon initiation/re-initiation of treatment, it is important to observe for signs and symptoms of bradycardia as well as AV conduction blocks, which may include overnight monitoring. Regular measurements of pulse rate and blood pressure are required, and ECGs should be performed.

There is no specific antidote to ponesimod. Neither dialysis nor plasma exchange would result in meaningful removal of ponesimod from the body. The decrease in heart rate induced by PONVORY® can be reversed by atropine.

In the event of overdose, PONVORY® should be discontinued, and general supportive treatment given until clinical toxicity has been diminished or resolved. It is advisable to contact a poison control center to obtain the latest recommendations for the management of an overdose.

ADVERSE REACTIONS

Most common adverse reactions (incidence at least 10%) are upper respiratory tract infection, hepatic transaminase elevation, and hypertension.

Please see full Prescribing Information and Medication Guide.

PON0053V2 06/24

References: 1. PONVORY®. Prescribing information. Vanda Pharmaceuticals, Inc; 2024. 2. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777-788. doi:10.1212/WNL.0000000000005347 3. Inojosa H, Proschmann U, Akgün K, Ziemssen T. The need for a strategic therapeutic approach: Multiple sclerosis in check. Ther Adv Chronic Dis. 2022;13:20406223211063032. doi:10.1177/20406223211063032 4. Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial. JAMA Neurol. 2021;78(5):558-567. doi:10.1001/jamaneurol.2021.0405 5. Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014;85:1198-1208. doi:10.1136/jnnp-2013-307282 6. ZEPOSIA® (ozanimod). Prescribing information. Celgene Corp; 2022. 7. MAYZENT® (siponimod). Prescribing information. Novartis Pharmaceuticals Corp; 2023. 8. GILENYA® (fingolimod). Prescribing information. Novartis Pharmaceuticals Corp; 2022.

INDICATION STATEMENT

PONVORY® is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Last updated: May 2024 | PON0106